Surrozen (SRZN) Set to Post Earnings on Friday

Surrozen (NASDAQ:SRZN) is anticipated to post its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Surrozen to post earnings of ($1.1039) per share and revenue of $0.47 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Surrozen (NASDAQ:SRZN) last released its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.88. The business had revenue of $5.00 million for the quarter, compared to the consensus estimate of $0.47 million. On average, analysts expect Surrozen to post ($1.01) EPS for the current fiscal year and ($4.19) EPS for the next fiscal year.

Surrozen Trading Up 3.8%

Shares of SRZN opened at $30.12 on Wednesday. The company has a 50-day moving average of $24.53 and a 200 day moving average of $25.07. Surrozen has a 1-year low of $11.39 and a 1-year high of $37.83.

Wall Street Analysts Forecast Growth

Several research analysts have commented on SRZN shares. William Blair assumed coverage on Surrozen in a report on Thursday, August 20th. They set an “outperform” rating and a $51.00 price objective on the stock. Zacks Research upgraded Surrozen from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, October 15th. Finally, HC Wainwright restated a “buy” rating and set a $54.00 price target (up from $44.00) on shares of Surrozen in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Surrozen presently has a consensus rating of “Moderate Buy” and an average target price of $48.33.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biotechnology company focused on developing regenerative medicines that selectively activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen is working to harness the pathway while limiting the potential safety risks associated with broad or uncontrolled activation.

The company uses its SWEETS (Surrozen Wnt Engineered Efficacious Therapeutics) platform to discover and engineer antibody-based medicines designed to modulate Wnt signaling in specific tissues.